Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Leptin signalling system as a target for pulmonary arterial hypertension therapy

Alice Huertas, Ly Tu, Raphaël Thuillet, Morane Le Hiress, Carole Phan, Nicolas Ricard, Sophie Nadaud, Elie Fadel, Marc Humbert, Christophe Guignabert
European Respiratory Journal 2015 45: 1066-1080; DOI: 10.1183/09031936.00193014
Alice Huertas
1INSERM UMR_S 999, Centre Chirurgical Marie Lannelongue, LabEx LERMIT, Le Plessis-Robinson, France
2Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ly Tu
1INSERM UMR_S 999, Centre Chirurgical Marie Lannelongue, LabEx LERMIT, Le Plessis-Robinson, France
2Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphaël Thuillet
1INSERM UMR_S 999, Centre Chirurgical Marie Lannelongue, LabEx LERMIT, Le Plessis-Robinson, France
2Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morane Le Hiress
1INSERM UMR_S 999, Centre Chirurgical Marie Lannelongue, LabEx LERMIT, Le Plessis-Robinson, France
2Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carole Phan
1INSERM UMR_S 999, Centre Chirurgical Marie Lannelongue, LabEx LERMIT, Le Plessis-Robinson, France
2Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Ricard
1INSERM UMR_S 999, Centre Chirurgical Marie Lannelongue, LabEx LERMIT, Le Plessis-Robinson, France
2Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Nadaud
4INSERM UMR_S 956, Université Pierre and Marie Curie, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elie Fadel
1INSERM UMR_S 999, Centre Chirurgical Marie Lannelongue, LabEx LERMIT, Le Plessis-Robinson, France
2Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Humbert
1INSERM UMR_S 999, Centre Chirurgical Marie Lannelongue, LabEx LERMIT, Le Plessis-Robinson, France
2Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Humbert
Christophe Guignabert
1INSERM UMR_S 999, Centre Chirurgical Marie Lannelongue, LabEx LERMIT, Le Plessis-Robinson, France
2Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Upregulation of leptin (Ob)/Ob main receptor (ObR-b) axis in human idiopathic pulmonary arterial hypertension (iPAH). a and b) Human pulmonary endothelial cells (P-ECs) as Ob in PAH. a) Representative images of in situ Ob staining (red) from controls and patients with iPAH, in which P-ECs are positive for lectin (green) and pulmonary arterial smooth muscle cells (PA-SMCs) are positive for SM22 (white). b) In vitro quantification of Ob production in conditioned media of primary early (≤5) passage cultures of human P-ECs from controls (n=15) and iPAH patients (n=10). c–e) Human and rodent PA-SMCs overexpress the ObR-b in PAH. c) Representative image of ObR-b (red) staining in PA-SMCs, positive for SM22 (white), in lungs from controls and iPAH patients, in which P-ECs are positive for lectin (green). d) Quantification of ObR-b mRNA level in primary early (≤5) passage cultures of human PA-SMCs from controls (n=10) and iPAH (n=10), and quantification for ObR-b/β-actin ratio in primary early (≤5) passage cultures of human PA-SMCs from controls (n=5) and iPAH (n=5) with representative Western blots. e) Quantification of ObR-b/β-actin ratio in rat lungs, from controls (n=5) and chronic hypoxia-induced pulmonary hypertension (PH) (n=5), with representative Western blot. f–i) Dichloroacetate (DCA) abolishes the excessive endothelial-derived Ob production. f) Schematic representation of the role of dimethyloxaloylglycine (DMOG) and DCA in Ob signalling pathway. PDK: pyruvate dehydrogenase kinase; PDH: pyruvate dehydrogenase; PHD: prolyl hydroxylase domains; HIF: hypoxia-inducible factor. g) Quantification of HIF-1α/β-actin ratio and a representative Western blot in primary early (≤5) passage cultures of human P-ECs from controls in untreated (vehicle, n=3), DMOG-treated (n=3) or DMOG+DCA-treated (n=3) conditions. h and i) Quantification of Ob production in conditioned media of primary early (≤5) passage cultures of human P-ECs from h) controls in untreated (n=3), DMOG-treated (n=3) or DMOG+DCA-treated (n=3) conditions and from i) human P-ECs from iPAH patients in untreated (n=3) or DCA-treated conditions (n=3). DAPI: 4',6-diamidino-2-phenylindole; AU: arbitrary unit. *: p<0.05; **: p<0.01. Scale bar=20 µm.

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Leptin (Ob)/Ob main receptor (ObR-b) axis contributes to pulmonary vascular remodelling in idiopathic pulmonary arterial hypertension (iPAH). a–c) The Ob/ObR-b axis induces human and rodent pulmonary arterial smooth muscle cell (PA-SMC) proliferation. a) Quantification of 5-bromo-2-deoxyuridine (BrdU) incorporation in primary early (≤5) passage cultures of PA-SMCs from controls and iPAH treated with increasing doses of recombinant Ob (n=3 for each condition and replicated three times). b) Quantification of mRNA levels of Ki67 and c) cyclin D1 in lungs from chronically hypoxic mice, treated or untreated (vehicle) with recombinant Ob (n=5 in each group). d–k) Ob/ObR-b axis induces monocyte activation in iPAH. d) Representative fluorescence-activated cell sorter (FACS) dot plots of peripheral blood mononuclear cells (PBMCs) withdrawn from controls (n=10) and iPAH patients (n=10), and stained with an anti-CD14 antibody. The red quadrants represent PBMCs positive for CD14 (CD14+ cells). SSC: side-scattered light. e) Quantification of CD14+ PMBCs. f) Representative FACS dot plots of PBMCs withdrawn from controls (n=10) and iPAH patients (n=10), and dual stained with anti-CD11b and CD25 antibodies. The red quadrants in the dot plots represent double-positive cells for CD11b and CD25 (CD11b+ CD25+ cells). g) Quantification of CD11b+ CD25+ PBMCs. h) Quantification of the number of CD14+ cells expressing ObR-b by FACS in controls (n=10) and iPAH patients (n=10). i) Quantification of the number of CD14+ PBMCs from controls (n=3) treated with increasing doses of recombinant Ob (n=3 in each condition, replicated three times). j) Representative FACS dot plots quantification of control PBMCs (n=3) treated with increasing doses of recombinant Ob double stained with anti-CD11b and CD25 antibodies. The red quadrants in the dot plots represent double-positive cells for CD11b and CD25 (CD11b+ CD25+ cells). k) Quantification of CD11b+ CD25+ PBMCs treated with increasing doses of recombinant Ob (n=3 in each condition, replicated three times). l–n) Ob/ObR-b axis induces overexpression of key adhesion molecules in human pulmonary endothelial cells (P-ECs). l) Quantification of mRNA levels of intercellular adhesion molecule (ICAM)-1, m) vascular cell adhesion molecule (VCAM)-1 and n) E-selectin in primary early (≤5) passage cultures of human P-ECs from controls (n=3) treated with increasing doses of recombinant Ob (n=3 in each condition, replicated three times). AU: arbitrary unit; ns: nonsignificant; #: normalised to untreated conditions. *: p<0.05; **: p<0.01; ***: p<0.001

  • FIGURE 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3

    Daily leptin (Ob) injections act on chronic hypoxia-induced pulmonary hypertension (PH). a and b) Murine model of chronic activation of Ob/Ob main receptor (Obr-b) axis. a) Experimental strategy of chronic recombinant Ob intraperitoneal (i.p.) injections in mice exposed to normoxia or hypoxia (n=5 in each condition). b) Body weight. c–f) Chronic Ob injections increase right ventricular systolic pressure (RVSP) in hypoxia-induced-PH. c) RVSP. d) Right ventricular hypertrophy measured by Fulton index normalised by body weight. e) Representative images of haematoxylin and eosin staining. Scale bar=50 μm. f) Quantification of the percentage of muscularised pulmonary arteries (PA) in mice. g–k) Chronic Ob injections enhance pulmonary arterial smooth muscle cell proliferation and perivascular macrophage activation. Representative images of g) proliferating cell nuclear antigen (PCNA), scale bar=50 µm and i) F4/80 markers, scale bar=20 µm. h and j) Quantification of cells expressing PCNA and F4/80 markers, respectively, in mice PA. k) Quantification of double-positive cells for CD206 and F4/80 in mice PA. ns: nonsignificant; *: p<0.05; **: p<0.01; ***: p<0.001.

  • FIGURE 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4

    Leptin (Ob)/Ob main receptor (ObR-b) axis enhances chronic hypoxia-induced pulmonary hypertension (PH) susceptibility. a and b) ObR-deficient Zucker Diabetic Fatty (ZDF) transgenic rats. a) Experimental strategy of ZDF transgenic rats exposed to normoxia or hypoxia (n=5 in each condition). b) Body weight. c–g) ObR-deficiency protects against chronic hypoxia-induced-PH development. c) Mean pulmonary arterial pressure (PAP), d) pulmonary vascular resistance (PVR), and e) right ventricular hypertrophy measured by Fulton index normalised by body weight. f) Representative images of haematoxylin and eosin stain (HE) and α-smooth muscle cell actin (α-SMA) and g) quantification of the percentage of muscularised pulmonary arteries (PA) in rat lungs. h–k) ObR-deficiency decreases pulmonary arterial smooth muscle cell proliferation and perivascular macrophage accumulation. h and j) Representative images of proliferating cell nuclear antigen (PCNA) and CD68 staining, respectively, in rat PA. i and k ) Quantification of cells expressing PCNA and CD68 markers, respectively, in rat PA. ns: nonsignificant; *: p<0.05; **: p<0.01. Scale bar=50 µm.

  • FIGURE 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5

    Targeting leptin (Ob)/Ob main receptor (ObR-b) axis with an Ob neutraliser (ObR:Fc) protects against pulmonary hypertension (PH) progression. a and b) Efficacy of an Ob neutraliser treatment in chronic hypoxia-induced PH. a) Quantification of 5-bromo-2-deoxyuridine (BrdU) incorporation in primary early (≤5) passage cultures of human pulmonary arterial smooth muscle cells (PA-SMCs) from controls exposed to the conditioned media of pulmonary endothelial cells (P-ECs) from idiopathic pulmonary arterial hypertension (iPAH) patients untreated (vehicle) or treated with ObR:Fc (n=3 in each condition). b) Experimental strategy of chronic ObR:Fc intraperitoneal (i.p.) injections in mice exposed to normoxia or hypoxia (n=5 in each condition). c–f) ObR:Fc treatment protects against chronic hypoxia induced PH progression. c) Right ventricular systolic pressure (RVSP), d) right ventricular hypertrophy measured by Fulton index, normalised by body weight, e) representative images of haematoxylin and eosin staining, and f) quantification of the percentage of muscularised pulmonary arteries (PA) in mice. g–k) ObR:Fc treatment increases PA-SMC proliferation and perivascular macrophage activation. Representative images of g) proliferating cell nuclear antigen (PCNA) and i) F4/80 staining. h and j) Quantification of cells expressing PCNA and F4/80 markers, respectively, in mice PA. k) Quantification of double-positive cells for CD206 and F4/80 in mice PA. ns: nonsignificant; *: p<0.05; **: p<0.01; ***: p<0.001. Scale bar=50 µm.

  • FIGURE 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6

    Chronic dichloroacetate (DCA) treatment modulates leptin (Ob)/Ob main receptor (ObR-b) axis in hypoxia-induced pulmonary hypertension (PH). a and b) Chronic DCA treatment abolishes endothelial-derived Ob production in hypoxia. a) Representative images of in situ Ob staining (red) in rat lungs exposed to normoxia or hypoxia, treated with or not treated with DCA at a concentration of 1 g·L-1, in which pulmonary endothelial cells (P-ECs) are positive for Tie2 (green). b) Experimental strategy of chronic DCA treatment in drinking water in rats exposed to normoxia or hypoxia (n=5 in each condition). c–g) DCA treatment protects against chronic hypoxia-induced PH progression. c) Mean pulmonary arterial pressure (PAP), d) pulmonary vascular resistance (PVR), and e) right ventricular hypertrophy measured by Fulton index normalised by body weight. f) Representative images of haematoxylin and eosin staining (HE) and α-smooth muscle cell actin (α-SMA). g) Quantification of the percentage of muscularised pulmonary arteries (PA) in rat lungs. h–k) DCA treatment decreases pulmonary arterial smooth muscle cell proliferation and perivascular macrophage accumulation. Representative images of stained h) proliferating cell nuclear antigen (PCNA) and j) CD68+. i and k) Quantification of cells expressing PCNA and CD68 markers, respectively, in rat PA. DAPI: 4',6-diamidino-2-phenylindole; ns: nonsignificant; *: p<0.05; ***: p<0.001. Scale bar=50 µm.

Tables

  • Figures
  • TABLE 1

    Characteristics of idiopathic pulmonary arterial hypertension (iPAH) patients and controls

    iPAHControls
    Patients1010
    Age years54.9±3.141.9±2.1
    Sex male/female (ratio)3/7 (0.43)4/6 (0.67)
    NYHA functional class
     Class I2NA
     Class II5NA
     Class III3NA
    6MWD m465±20NA
    Mean PAP mmHg48.8±3.5NA
    Cardiac index Lmin−1·m−22.9±0.2NA
    PVRI Wood unit·m−28.3±0.9NA
    PCWP mmHg8.4±0.7NA
    Specific PAH therapy
     ERA8NA
     PDE5i6NA
     Prostanoids2NA
     No treatment0NA
    • Data are presented as n or mean±sem, unless otherwise stated. NYHA: New York Heart Association; 6MWD: 6-min walking distance; PAP: pulmonary arterial pressure; PVRI: pulmonary vascular resistance index; PCWP: pulmonary capillary wedge pressure; ERA: endothelin receptor antagonists; PDE5i: phophodiesterase 5 inhibitors; NA: not applicable.

  • TABLE 2

    Characteristics of transplanted idiopathic pulmonary arterial hypertension (iPAH) patients and lung resected subjects (controls)

    iPAHControls
    Patients77
    Age years39.8±2.246.4±2.3
    Sex male/female (ratio)2/5 (0.40)2/5 (0.40)
    Mutation in BMPR2 gene
     Carrier0NA
     Non-carrier7NA
    NYHA functional class
     Class III2NA
     Class IV5NA
    Mean PAP mmHg69.9±2.1NA
    Cardiac index L·min−1·m−22.6±0.1NA
    PVRI Wood unit·m−214.6±0.6NA
    PCWP mmHg8±0.5NA
    • Data are presented as n or mean±sem, unless otherwise stated. NYHA: New York Heart Association; PAP: pulmonary arterial pressure; PVRI: pulmonary vascular resistance index; PCWP: pulmonary capillary wedge pressure; NA: not applicable.

PreviousNext
Back to top
View this article with LENS
Vol 45 Issue 4 Table of Contents
European Respiratory Journal: 45 (4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Leptin signalling system as a target for pulmonary arterial hypertension therapy
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Leptin signalling system as a target for pulmonary arterial hypertension therapy
Alice Huertas, Ly Tu, Raphaël Thuillet, Morane Le Hiress, Carole Phan, Nicolas Ricard, Sophie Nadaud, Elie Fadel, Marc Humbert, Christophe Guignabert
European Respiratory Journal Apr 2015, 45 (4) 1066-1080; DOI: 10.1183/09031936.00193014

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Leptin signalling system as a target for pulmonary arterial hypertension therapy
Alice Huertas, Ly Tu, Raphaël Thuillet, Morane Le Hiress, Carole Phan, Nicolas Ricard, Sophie Nadaud, Elie Fadel, Marc Humbert, Christophe Guignabert
European Respiratory Journal Apr 2015, 45 (4) 1066-1080; DOI: 10.1183/09031936.00193014
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Allergen inhalation associated with airway dysfunction
  • OSTEOPOROSIS AND FACTURE RISK ASSOCIATED WITH ICS USE IN COPD
  • Cost-effectiveness of azithromycin in reducing asthma exacerbations
Show more Original Articles

Pulmonary vascular diseases

  • Fibrinogen and residual obstruction after pulmonary embolism treatment
  • Risk assessment in medically treated CTEPH patients
  • Exercise RHC, pulmonary endarterectomy in chronic thromboembolic disease
Show more Pulmonary vascular diseases

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society